Friday, July 10, 2026

pharma · Breast Cancer · Multiple Sclerosis (MS)

HOFFMANN-LA ROCHE

Hoffmann-La Roche is a pharma organization headquartered in Basel, CH. Primary therapeutic focus areas include Breast Cancer, Multiple Sclerosis (MS), Spinal Muscular Atrophy (SMA), Non-Small Cell Lung Cancer, Solid Tumo

Mississauga, Ontario L5N 5M8, CA HQ
10 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Mississauga, Ontario L5N 5M8, CA
Employees
10
Programs
286
Drugs
212
Patents
0
Clinical program

MN45053

Phase 3 · small molecule · Neurological Disease

MN45053 for Neurological Disease is a Phase 3 program (small_molecule) at Hoffmann-La Roche with 1 ClinicalTrials.gov record(s).

← All Hoffmann-La Roche projects Phase 3 small molecule active

Internal code MN45053

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Hoffmann-La Roche
Phase
Phase 3
Modality
small_molecule
Indication
Neurological Disease
Status
active
Trials
1